With a budget of over half a billion dollars, Johnson & Johnson has outlined its ambitious strategy to collaborate with public and private partners to accelerate efforts to eliminate HIV and tubercu
Johnson & Johnson is maintaining that its planned $400 price for a six-month course of bedaquiline that kicks in early this month for many tuberculosis-affected countries is sustainable and fair. “Th
"The Pink Sheet" regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy transactions that occurred between Dec. 18-D
IN VITRO DIAGNOSTICS Mergers & Acquisitions Cooper Cos. Inc. CooperSurgical Inc. Reprogenetics LLC CooperSurgical Inc. , the women’s health business unit of Cooper Cos. Inc. , paid $46.5mm to ac